Olanzapine-induced hypertriglyceridemia in cancer care: A silent metabolic risk
Olanzapine (Zyprexa), an atypical antipsychotic, is used off-label for managing nausea in advanced cancer patients but is linked to severe metabolic side effects, including hypertriglyceridemia. This case involves a metastatic gastric carcinoma patient with no known metabolic disorder who developed...
Saved in:
| Main Authors: | Bilal Kazi, Imaan Rumani, Marzooka Nazim Chishti Kazi, Prashant Manohar Gaikwad |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Current Problems in Cancer: Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621924000668 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Olanzapine: The game-changer “antiemetic”
by: Manikandan Dhanushkodi
Published: (2019-01-01) -
Efficacy of olanzapine as an antiemetic drug for transcatheter arterial chemoembolization for hepatocellular carcinoma
by: Kyoko Oura, et al.
Published: (2025-05-01) -
Hypertriglyceridemia — current status of the problem. Part II: primary and secondary hypertriglyceridemias, treatment options
by: A. A. Semenkin, et al.
Published: (2025-03-01) -
Olanzapine-induced neutropenia
by: Kirti Malhotra, et al.
Published: (2015-06-01) -
Olanzapine-induced Pancytopenia: Case Report
by: A Prajnashree, et al.
Published: (2024-11-01)